Intrinsic value of Syneos Health Cl A - SYNH

Previous Close

$49.70

  Intrinsic Value

$253.52

stock screener

  Rating & Target

str. buy

+410%

Previous close

$49.70

 
Intrinsic value

$253.52

 
Up/down potential

+410%

 
Rating

str. buy

We calculate the intrinsic value of SYNH stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  4,275
  6,605
  9,878
  14,333
  20,222
  27,800
  37,316
  48,998
  63,049
  79,636
  98,889
  120,902
  145,727
  173,387
  203,872
  237,152
  273,179
  311,895
  353,238
  397,144
  443,557
  492,428
  543,721
  597,411
  653,491
  711,968
  772,867
  836,229
  902,110
  970,585
Variable operating expenses, $m
  3,526
  5,143
  7,416
  10,508
  14,596
  19,857
  26,463
  34,574
  44,328
  55,843
  68,651
  83,933
  101,167
  120,369
  141,533
  164,637
  189,648
  216,525
  245,226
  275,707
  307,928
  341,856
  377,464
  414,737
  453,669
  494,266
  536,543
  580,530
  626,267
  673,804
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,526
  5,143
  7,416
  10,508
  14,596
  19,857
  26,463
  34,574
  44,328
  55,843
  68,651
  83,933
  101,167
  120,369
  141,533
  164,637
  189,648
  216,525
  245,226
  275,707
  307,928
  341,856
  377,464
  414,737
  453,669
  494,266
  536,543
  580,530
  626,267
  673,804
Operating income, $m
  749
  1,462
  2,463
  3,825
  5,625
  7,943
  10,852
  14,425
  18,721
  23,793
  30,238
  36,969
  44,560
  53,017
  62,339
  72,515
  83,532
  95,370
  108,011
  121,437
  135,629
  150,573
  166,257
  182,674
  199,822
  217,703
  236,324
  255,698
  275,843
  296,781
EBITDA, $m
  1,457
  2,251
  3,366
  4,884
  6,890
  9,472
  12,714
  16,695
  21,482
  27,133
  33,694
  41,194
  49,652
  59,076
  69,463
  80,802
  93,078
  106,269
  120,355
  135,315
  151,129
  167,780
  185,257
  203,550
  222,658
  242,582
  263,331
  284,920
  307,367
  330,698
Interest expense (income), $m
  0
  162
  300
  501
  782
  1,166
  1,673
  2,325
  3,144
  4,150
  5,359
  6,787
  8,444
  10,339
  12,476
  14,857
  17,481
  20,345
  23,446
  26,779
  30,338
  34,117
  38,112
  42,319
  46,734
  51,355
  56,182
  61,216
  66,458
  71,912
  77,582
Earnings before tax, $m
  587
  1,162
  1,962
  3,042
  4,460
  6,270
  8,527
  11,280
  14,571
  18,434
  23,451
  28,525
  34,221
  40,542
  47,482
  55,035
  63,186
  71,924
  81,232
  91,099
  101,512
  112,461
  123,938
  135,940
  148,467
  161,520
  175,108
  189,241
  203,932
  219,199
Tax expense, $m
  158
  314
  530
  821
  1,204
  1,693
  2,302
  3,046
  3,934
  4,977
  6,332
  7,702
  9,240
  10,946
  12,820
  14,859
  17,060
  19,419
  21,933
  24,597
  27,408
  30,364
  33,463
  36,704
  40,086
  43,610
  47,279
  51,095
  55,062
  59,184
Net income, $m
  429
  848
  1,432
  2,221
  3,255
  4,577
  6,225
  8,235
  10,637
  13,457
  17,119
  20,823
  24,981
  29,595
  34,662
  40,175
  46,126
  52,504
  59,300
  66,503
  74,104
  82,096
  90,475
  99,236
  108,381
  117,910
  127,829
  138,146
  148,870
  160,015

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  11,649
  17,998
  26,916
  39,054
  55,100
  75,750
  101,678
  133,510
  171,795
  216,991
  269,453
  329,432
  397,077
  472,443
  555,509
  646,190
  744,357
  849,851
  962,500
  1,082,136
  1,208,602
  1,341,766
  1,481,528
  1,627,823
  1,780,629
  1,939,968
  2,105,905
  2,278,552
  2,458,066
  2,644,647
Adjusted assets (=assets-cash), $m
  11,649
  17,998
  26,916
  39,054
  55,100
  75,750
  101,678
  133,510
  171,795
  216,991
  269,453
  329,432
  397,077
  472,443
  555,509
  646,190
  744,357
  849,851
  962,500
  1,082,136
  1,208,602
  1,341,766
  1,481,528
  1,627,823
  1,780,629
  1,939,968
  2,105,905
  2,278,552
  2,458,066
  2,644,647
Revenue / Adjusted assets
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
  0.367
Average production assets, $m
  2,689
  4,155
  6,213
  9,015
  12,719
  17,486
  23,472
  30,820
  39,658
  50,091
  62,201
  76,047
  91,662
  109,060
  128,235
  149,169
  171,830
  196,182
  222,186
  249,803
  278,997
  309,737
  342,000
  375,772
  411,046
  447,828
  486,133
  525,988
  567,427
  610,498
Working capital, $m
  -30
  -46
  -69
  -100
  -142
  -195
  -261
  -343
  -441
  -557
  -692
  -846
  -1,020
  -1,214
  -1,427
  -1,660
  -1,912
  -2,183
  -2,473
  -2,780
  -3,105
  -3,447
  -3,806
  -4,182
  -4,574
  -4,984
  -5,410
  -5,854
  -6,315
  -6,794
Total debt, $m
  5,559
  9,273
  14,490
  21,591
  30,978
  43,058
  58,226
  76,848
  99,244
  125,684
  156,375
  191,462
  231,034
  275,124
  323,717
  376,766
  434,193
  495,907
  561,807
  631,794
  705,777
  783,678
  865,438
  951,021
  1,040,413
  1,133,626
  1,230,699
  1,331,697
  1,436,713
  1,545,863
Total liabilities, $m
  6,815
  10,529
  15,746
  22,847
  32,233
  44,314
  59,482
  78,103
  100,500
  126,940
  157,630
  192,718
  232,290
  276,379
  324,973
  378,021
  435,449
  497,163
  563,063
  633,049
  707,032
  784,933
  866,694
  952,277
  1,041,668
  1,134,881
  1,231,954
  1,332,953
  1,437,968
  1,547,118
Total equity, $m
  4,834
  7,469
  11,170
  16,208
  22,866
  31,436
  42,196
  55,407
  71,295
  90,051
  111,823
  136,714
  164,787
  196,064
  230,536
  268,169
  308,908
  352,688
  399,438
  449,086
  501,570
  556,833
  614,834
  675,547
  738,961
  805,087
  873,951
  945,599
  1,020,097
  1,097,528
Total liabilities and equity, $m
  11,649
  17,998
  26,916
  39,055
  55,099
  75,750
  101,678
  133,510
  171,795
  216,991
  269,453
  329,432
  397,077
  472,443
  555,509
  646,190
  744,357
  849,851
  962,501
  1,082,135
  1,208,602
  1,341,766
  1,481,528
  1,627,824
  1,780,629
  1,939,968
  2,105,905
  2,278,552
  2,458,065
  2,644,646
Debt-to-equity ratio
  1.150
  1.240
  1.300
  1.330
  1.350
  1.370
  1.380
  1.390
  1.390
  1.400
  1.400
  1.400
  1.400
  1.400
  1.400
  1.400
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
  1.410
Adjusted equity ratio
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  429
  848
  1,432
  2,221
  3,255
  4,577
  6,225
  8,235
  10,637
  13,457
  17,119
  20,823
  24,981
  29,595
  34,662
  40,175
  46,126
  52,504
  59,300
  66,503
  74,104
  82,096
  90,475
  99,236
  108,381
  117,910
  127,829
  138,146
  148,870
  160,015
Depreciation, amort., depletion, $m
  707
  789
  903
  1,059
  1,264
  1,529
  1,862
  2,270
  2,761
  3,341
  3,456
  4,225
  5,092
  6,059
  7,124
  8,287
  9,546
  10,899
  12,344
  13,878
  15,500
  17,208
  19,000
  20,876
  22,836
  24,879
  27,007
  29,222
  31,524
  33,917
Funds from operations, $m
  1,136
  1,637
  2,335
  3,280
  4,520
  6,106
  8,087
  10,505
  13,398
  16,797
  20,575
  25,048
  30,074
  35,654
  41,786
  48,462
  55,672
  63,403
  71,643
  80,381
  89,604
  99,304
  109,475
  120,112
  131,216
  142,789
  154,836
  167,367
  180,394
  193,932
Change in working capital, $m
  -11
  -16
  -23
  -31
  -41
  -53
  -67
  -82
  -98
  -116
  -135
  -154
  -174
  -194
  -213
  -233
  -252
  -271
  -289
  -307
  -325
  -342
  -359
  -376
  -393
  -409
  -426
  -444
  -461
  -479
Cash from operations, $m
  1,147
  1,653
  2,358
  3,311
  4,561
  6,159
  8,153
  10,587
  13,496
  16,913
  20,710
  25,202
  30,247
  35,848
  42,000
  48,695
  55,924
  63,674
  71,933
  80,688
  89,929
  99,646
  109,834
  120,488
  131,609
  143,199
  155,263
  167,811
  180,855
  194,411
Maintenance CAPEX, $m
  -93
  -149
  -231
  -345
  -501
  -707
  -971
  -1,304
  -1,712
  -2,203
  -2,783
  -3,456
  -4,225
  -5,092
  -6,059
  -7,124
  -8,287
  -9,546
  -10,899
  -12,344
  -13,878
  -15,500
  -17,208
  -19,000
  -20,876
  -22,836
  -24,879
  -27,007
  -29,222
  -31,524
New CAPEX, $m
  -1,008
  -1,466
  -2,059
  -2,802
  -3,704
  -4,767
  -5,985
  -7,348
  -8,838
  -10,433
  -12,111
  -13,846
  -15,615
  -17,398
  -19,175
  -20,933
  -22,661
  -24,352
  -26,004
  -27,617
  -29,194
  -30,740
  -32,263
  -33,771
  -35,274
  -36,782
  -38,305
  -39,854
  -41,439
  -43,071
Cash from investing activities, $m
  -1,101
  -1,615
  -2,290
  -3,147
  -4,205
  -5,474
  -6,956
  -8,652
  -10,550
  -12,636
  -14,894
  -17,302
  -19,840
  -22,490
  -25,234
  -28,057
  -30,948
  -33,898
  -36,903
  -39,961
  -43,072
  -46,240
  -49,471
  -52,771
  -56,150
  -59,618
  -63,184
  -66,861
  -70,661
  -74,595
Free cash flow, $m
  45
  38
  69
  164
  356
  686
  1,197
  1,934
  2,946
  4,277
  5,816
  7,900
  10,407
  13,358
  16,766
  20,638
  24,976
  29,776
  35,029
  40,727
  46,857
  53,406
  60,363
  67,717
  75,459
  83,580
  92,078
  100,949
  110,194
  119,816
Issuance/(repayment) of debt, $m
  2,552
  3,714
  5,217
  7,101
  9,387
  12,080
  15,168
  18,622
  22,397
  26,440
  30,691
  35,088
  39,572
  44,089
  48,594
  53,049
  57,428
  61,714
  65,900
  69,987
  73,983
  77,901
  81,761
  85,583
  89,392
  93,213
  97,073
  100,999
  105,016
  109,150
Issuance/(repurchase) of shares, $m
  1,383
  1,787
  2,269
  2,816
  3,403
  3,993
  4,535
  4,975
  5,251
  5,300
  4,653
  4,068
  3,091
  1,682
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  3,935
  5,501
  7,486
  9,917
  12,790
  16,073
  19,703
  23,597
  27,648
  31,740
  35,344
  39,156
  42,663
  45,771
  48,594
  53,049
  57,428
  61,714
  65,900
  69,987
  73,983
  77,901
  81,761
  85,583
  89,392
  93,213
  97,073
  100,999
  105,016
  109,150
Total cash flow (excl. dividends), $m
  3,980
  5,539
  7,555
  10,081
  13,146
  16,759
  20,900
  25,531
  30,594
  36,016
  41,159
  47,057
  53,070
  59,129
  65,359
  73,687
  82,403
  91,489
  100,929
  110,714
  120,839
  131,307
  142,124
  153,300
  164,850
  176,793
  189,151
  201,948
  215,210
  228,966
Retained Cash Flow (-), $m
  -1,812
  -2,635
  -3,701
  -5,037
  -6,659
  -8,570
  -10,760
  -13,210
  -15,888
  -18,756
  -21,772
  -24,891
  -28,072
  -31,277
  -34,472
  -37,633
  -40,739
  -43,780
  -46,750
  -49,649
  -52,483
  -55,263
  -58,001
  -60,713
  -63,415
  -66,125
  -68,864
  -71,649
  -74,498
  -77,431
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  2,168
  2,904
  3,854
  5,043
  6,488
  8,189
  10,140
  12,321
  14,706
  17,260
  19,388
  22,165
  24,998
  27,852
  30,887
  36,054
  41,664
  47,710
  54,180
  61,065
  68,356
  76,044
  84,123
  92,587
  101,436
  110,668
  120,287
  130,299
  140,711
  151,535
Discount rate, %
  8.30
  8.72
  9.15
  9.61
  10.09
  10.59
  11.12
  11.68
  12.26
  12.88
  13.52
  14.20
  14.91
  15.65
  16.43
  17.26
  18.12
  19.02
  19.97
  20.97
  22.02
  23.12
  24.28
  25.49
  26.77
  28.11
  29.51
  30.99
  32.54
  34.16
PV of cash for distribution, $m
  2,002
  2,457
  2,963
  3,494
  4,012
  4,476
  4,846
  5,092
  5,192
  5,141
  4,805
  4,507
  4,106
  3,637
  3,152
  2,824
  2,457
  2,076
  1,703
  1,355
  1,046
  783
  567
  398
  270
  177
  112
  68
  40
  22
Current shareholders' claim on cash, %
  78.7
  64.6
  54.7
  47.6
  42.4
  38.4
  35.4
  33.1
  31.3
  30.0
  29.1
  28.5
  28.1
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9
  27.9

FINANCIAL RATIOS  of  Syneos Health Cl A (SYNH)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

SYNH stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SYNH stock intrinsic value calculation we used $2672.064 million for the last fiscal year's total revenue generated by Syneos Health Cl A. The default revenue input number comes from 0001 income statement of Syneos Health Cl A. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SYNH stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8.3%, whose default value for SYNH is calculated based on our internal credit rating of Syneos Health Cl A, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Syneos Health Cl A.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SYNH stock the variable cost ratio is equal to 90.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for SYNH stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Syneos Health Cl A.

Corporate tax rate of 27% is the nominal tax rate for Syneos Health Cl A. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SYNH stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SYNH are equal to 62.9%.

Life of production assets of 18 years is the average useful life of capital assets used in Syneos Health Cl A operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SYNH is equal to -0.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $3022.579 million for Syneos Health Cl A - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 102.781 million for Syneos Health Cl A is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Syneos Health Cl A at the current share price and the inputted number of shares is $5.1 billion.

COMPANY NEWS

▶ Syneos Health Announces Corporate Leadership Positions   [Nov-14-18 04:15PM  GlobeNewswire]
▶ IBD 50 Stocks To Watch: This Leading Medical Company Beats Views   [Nov-07-18 02:42PM  Investor's Business Daily]
▶ Syneos Health: 3Q Earnings Snapshot   [06:42AM  Associated Press]
▶ Syneos Health: 2Q Earnings Snapshot   [09:23AM  Associated Press]
▶ Syneos Health to Present at Upcoming Investors Conferences   [May-21-18 04:15PM  GlobeNewswire]
▶ Syneos Health: 1Q Earnings Snapshot   [May-09-18 08:08AM  Associated Press]
▶ Perimeter Five gets new equity partner to complete Syneos HQ   [Apr-30-18 08:46AM  American City Business Journals]
▶ Does Syneos Health Inc (NASDAQ:SYNH) Go Up With The Market?   [Apr-20-18 05:22PM  Simply Wall St.]
▶ Should You Buy Syneos Health Inc (NASDAQ:SYNH) Now?   [Feb-28-18 07:31PM  Simply Wall St.]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.